Alvotech公司的股票暴跌了34%,因为林业发展局由于未解决的问题而拒绝提供药品,引发了一次欺诈调查。 Alvotech's stock plummeted 34% after FDA rejected its drug due to unresolved issues, prompting a fraud probe.

2025年11月16日, Levi & Korsinsky LLP(Levi & Korsinsky LLP)就Alvotech(ALVO)公司在2025年11月2日之后可能违反联邦证券法的行为,对Alvotech(ALVO)发起证券欺诈调查,宣布林业发展局就ATV05药物发布全面反应函,指出尽管提出了纠正计划,但仍有未解决的缺陷。 On November 16, 2025, Levi & Korsinsky LLP launched a securities fraud investigation into Alvotech (ALVO) over potential violations of federal securities laws following the company’s November 2, 2025, announcement that the FDA issued a Complete Response Letter for its drug ATV05, citing unresolved deficiencies despite a submitted corrective plan. 这一消息导致Alvotech的股票在11月3日前跌至5.03美元, 超过34%, The news caused Alvotech’s stock to drop over 34% to $5.03 by November 3. 该公司正在审查投资者是否被误导于药品的批准前景或监管合规。 The firm is examining whether investors were misled about the drug’s approval prospects or regulatory compliance.